Paritaprevir
TECHNIVIE
Pronunciation: par-i-TA-pre-veer (TEK-ni-vee)
What it isHCV NS3/4A protease inhibitor given with ritonavir; hepatitis C.
Why this oneRitonavir boosting allowed once-daily dosing of an otherwise short-lived protease inhibitor.
What limits itContraindicated in decompensated cirrhosis. Superseded; extensive CYP3A4 interactions.
FDA-approved for
- chronic hepatitis C (2014)
NO BOXED WARNINGS
Principal riskContraindicated in decompensated cirrhosis
Classes and tags
Clinical profile
Legacy pregnancy categoryN/A (post-2015 labeling)
Defining liabilityHepatic decompensation, HBV reactivation and major drug interactions